Literature DB >> 29198609

Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.

Seul Ki Yeon1, Ji Won Choi1, Jong-Hyun Park2, Ye Rim Lee3, Hyeon Jeong Kim1, Su Jeong Shin1, Bo Ko Jang2, Siwon Kim4, Yong-Sun Bahn5, Gyoonhee Han5, Yong Sup Lee6, Ae Nim Pae7, Ki Duk Park8.   

Abstract

Benzyloxyphenyl moiety is a common structure of highly potent, selective and reversible inhibitors of monoamine oxidase B (MAO-B), safinamide and sembragiline. We synthesized 4-(benzyloxy)phenyl and biphenyl-4-yl derivatives including halogen substituents on the terminal aryl unit. In addition, we modified the carbon linker between amine group and the biaryl linked unit. Among synthesized compounds, 12c exhibited the most potent and selective MAO-B inhibitory effect (hMAO-B IC50: 8.9 nM; >10,000-fold selectivity over MAO-A) as a competitive inhibitor. In addition, 12c showed greater MAO-B inhibitory activity and selectivity compared to well-known MAO-B inhibitors such as selegiline, safinamide and sembragiline. In the MPTP-induced mouse model of Parkinson's disease (PD), 12c significantly protected the tyrosine hydroxylase (TH)-immunopositive DAergic neurons and attenuated the PD-associated behavioral deficits. This study suggests characteristic structures as a MAO-B inhibitor that may provide a good insight for the development of therapeutic agents for PD.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Benzyloxyphenyl derivatives; MAO-B inhibitor; MPTP mouse model; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 29198609     DOI: 10.1016/j.bmc.2017.11.036

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

2.  KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease.

Authors:  Min-Ho Nam; Jong-Hyun Park; Hyo Jung Song; Ji Won Choi; Siwon Kim; Bo Ko Jang; Hyung Ho Yoon; Jun Young Heo; Hyowon Lee; Heeyoung An; Hyeon Jeong Kim; Sun Jun Park; Doo-Wan Cho; Young-Su Yang; Su-Cheol Han; Sangwook Kim; Soo-Jin Oh; Sang Ryong Jeon; Ki Duk Park; C Justin Lee
Journal:  Neurotherapeutics       Date:  2021-10-05       Impact factor: 7.620

3.  Synthesis and Antimycobacterial Evaluation of N-(4-(Benzyloxy)benzyl)-4-aminoquinolines.

Authors:  Estevão Silveira Grams; Alessandro Silva Ramos; Mauro Neves Muniz; Raoní S Rambo; Marcia Alberton Perelló; Nathalia Sperotto; Laura Calle González; Lovaine Silva Duarte; Luiza Galina; Adilio Silva Dadda; Guilherme Arraché Gonçalves; Cristiano Valim Bizarro; Luiz Augusto Basso; Pablo Machado
Journal:  Molecules       Date:  2022-04-15       Impact factor: 4.927

4.  Discovery of N-(1-(3-fluorobenzoyl)-1H-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B.

Authors:  Ahmed Elkamhawy; Sora Paik; Hyeon Jeong Kim; Jong-Hyun Park; Ashwini M Londhe; Kyeong Lee; Ae Nim Pae; Ki Duk Park; Eun Joo Roh
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.